- Price is above the Trend Line, keeping the weekly tape constructive.
- Price is above Fair Value, showing premium demand versus the model.
- Activity pressure is positive on the latest completed week.
- Volume is elevated versus the 13-week average, confirming attention.
H6D0
GER
Week ended 07 Aug 2026
Weekly Investor Report
Haleon plc · Healthcare · Drug Manufacturers - Specialty & Generic
Latest close
4.32 EUR
0.8%
latest week
Weekly setup
Mixed setup
The weekly trend is not active. Price is 2.4% above the Trend Line and sits at 59.9% of its 52-week range. The latest completed week returned 0.8%, after a 1.4% four-week move. The latest factor snapshot indicates quality ranks strongly versus its universe; growth is moderate; valuation is neither clearly cheap nor expensive. The latest news-sentiment score is 54/100.
Setup score
54
out of 100
Latest Close
4.32 EUR
7 Aug 2026
1W Return
0.8%
latest completed week
4W Return
1.4%
short-term follow-through
12W Return
12.6%
quarterly tape
Trend Breadth
25.0%
13 of 52 weeks active
Volume Ratio
3.0x
vs 13-week average
- The trend backdrop is inactive, so price action has not confirmed a constructive regime.
- Activity pressure is weak, so confirmation is not yet broad enough.
- Trend Line remains the key weekly regime level.
- Activity pressure is the gauge to monitor for confirmation or fade.
- A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through
0.8%
Latest completed week; four-week move 1.4%.
Indicator stack
14/100
Trend and activity pressure are weighted against the latest 12-week confirmation window.
Trend backdrop
Active
The trend backdrop defines the current weekly regime.
Patient Capital
Quiet
Activity-pressure buy-signal status for institutional accumulation timing.
News sentiment
54/100
6 relevant articles in the latest sentiment read.
01 · Price action
Study the full chart
Where price is—and whether the trend supports it
The weekly trend is not active. Price is 2.4% above the Trend Line and sits at 59.9% of its 52-week range. The latest completed week returned 0.8%, after a 1.4% four-week move.
52-week price path
Price vs Trend Line and Fair Value
Price
Trend Line
Fair Value
02 · Volume and demand
Is real participation confirming the move?
Latest weekly volume is 3.0x the 13-week average. Participation is unusually strong and confirms that the move is attracting attention.
26-week volume confirmation
Bar height shows volume; colour shows the weekly price direction
13 Feb
20 Feb
27 Feb
6 Mar
13 Mar
20 Mar
27 Mar
3 Apr
10 Apr
17 Apr
24 Apr
1 May
8 May
15 May
22 May
29 May
5 Jun
12 Jun
19 Jun
26 Jun
3 Jul
10 Jul
17 Jul
24 Jul
31 Jul
7 Aug
Up week
Down week
Demand beneath price
Activity pressure and institutional-style signals
These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.
Activity pressure path
Latest 0.3012-week average 0.19
12-week confirmation
Trend active0/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure4/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership2/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.30Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers
No recent accumulation markers. No reversal markers.
03 · Momentum and leadership
Is performance persistent—and is the stock leading?
Performance is 1.4% over four weeks, 12.6% over 12 weeks, and 7.7% over one year. The current trend has remained active for 0 consecutive weeks.
Performance by holding period
Active trend streak0 weeks
Active weeks in one year13
Trend breadth25.0%
Activity pressure vs relative leadership
Activity pressureRelative leadership
Pressure1.03Latest activity-pressure read.
Pressure change519.7%Four-week change in activity pressure.
Leadership-3.89Latest relative-leadership reading.
RS change-703.9%Four-week change in relative leadership.
04 · Fundamentals and valuation
Open full factor analysis
What investors are paying for—and the quality behind it
The latest factor snapshot indicates quality ranks strongly versus its universe; growth is moderate; valuation is neither clearly cheap nor expensive.
Factor week 09 Aug 2026
Financial statements through 31 Dec 2025
Field coverage 91%
Model confidence 72%
Relative factor standing
Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.
Overall factor strength43/100Blend of value, momentum, and quality. Underlying universe rank 58; rank 1 is best.
Value28/100Relative valuation strength. Underlying universe rank 73; rank 1 is best.
Quality88/100Profitability and accounting quality. Underlying universe rank 13; rank 1 is best.
Momentum45/100Medium-term price momentum. Underlying universe rank 56; rank 1 is best.
Growth36/100Revenue and earnings growth. Underlying universe rank 65; rank 1 is best.
Quality and valuation are separate questions
A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.
Valuation
How much investors are paying for earnings, sales, and cash flow.
- P/E
- 22.8x Price divided by trailing earnings.
- Price / sales
- 3.4x Market value relative to trailing revenue.
- EV / EBITDA
- 15.9x Enterprise value relative to operating cash earnings.
- Free-cash-flow yield
- 4.9% Free cash flow as a share of enterprise value.
Business quality
Margins and the return generated on invested capital.
- Gross margin
- 64.2% Gross profit retained from each unit of revenue.
- Operating margin
- 21.9% Operating profit retained from revenue.
- Free-cash-flow margin
- 20.1% Free cash flow generated from revenue.
- Return on invested capital
- 7.6% Operating return generated on invested capital.
Growth and financial strength
Recent business growth and accounting strength.
- Revenue growth
- -1.8% Latest one-year revenue growth.
- EPS growth
- 18.4% Latest one-year earnings-per-share growth.
- Free-cash-flow growth
- 12.0% Latest one-year free-cash-flow growth.
- Piotroski F-score
- 8/9 Nine-point accounting-strength checklist.
Shareholder return and balance sheet
Cash returned to owners and financial leverage.
- Dividend yield
- 1.9% Cash dividends relative to market value.
- Buyback yield
- 1.7% Net share repurchases relative to market value.
- Shareholder yield
- 3.6% Dividend yield plus net buyback yield.
- Net debt / EBITDA
- 2.6x Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment
What other market participants are doing
Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.
Insider activity-
No recent insider transactions are stored for this company.
News sentiment54/100
Weighted news tone is neutral across 6 relevant articles.
1 positive · 3 neutral · 2 negativePatient CapitalQuiet
Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal
06 · Catalysts and risk
What can move the shares—and how volatile the path has been
Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.
Next earnings-No event is currently stored.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-8.6%Distance below the 52-week high.
13-week volatility2.7%Standard deviation of weekly returns.
Weekly gains and losses
Latest 26 completed weeksEach bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.
13 Feb
13 Mar
10 Apr
8 May
5 Jun
3 Jul
7 Aug
Weeks higher11 of 2615 weeks finished lower.
Best week+5.9%Week of 26 Jun.
Worst week-5.7%Week of 6 Mar.
Latest week+0.8%Week of 7 Aug.
Shape of recent returns
Strong gains3
Modest gains8
Flat weeks0
Modest losses14
Sharp losses1
Recent vol2.7%13-week weekly-return volatility.
Base vol2.6%52-week weekly-return volatility.
Up/down split25/27Count of positive and negative weeks in the 52-week window.
Average skew2.3% / -1.7%Average positive week versus average negative week.
07 · Sector and peer context
Is this stock leading—or simply moving with its group?
Sector and industry breadth distinguish company-specific strength from a broad group move.
SectorDE Healthcare
4-week rank33 / 78
Group average1.4%
Trend breadth39.7%
Trend39.7%active weekly trend signals
MD69.2%positive activity pressure
RS34.6%positive relative leadership
Four-week leaders
IndustryDE Drug Manufacturers - Specialty & Generic
4-week rank5 / 10
Group average-3.6%
Trend breadth30.0%
Trend30.0%active weekly trend signals
MD40.0%positive activity pressure
RS30.0%positive relative leadership
Four-week leaders
08 · Evidence and weekly data
The underlying research record
Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.
Weekly tape49/100
Trend, activity pressure, participation, and risk combine to a 49/100 tape read.
Indicator analysis24/100Latest 12-week confirmation: trend 0/12, activity pressure 4/12, relative leadership 2/12.
Activity pressure 0.30; No reversal markers Factors51/100O'Shaughnessy factor stack blends value, quality, momentum, and confidence.
Buyback Yield rank 23; Small Cap Core rank 74 Patient CapitalQuietActivity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal Sentiment54/100Weighted news tone is neutral across 6 relevant articles.
Haleon PLC Revenue Breakdown – SWB:H6D0 Insiders50/100No recent insider transaction evidence is stored.
Earnings50/100No stored earnings event is currently attached to this ticker.
| Week | Close | Return | Trend Line | Fair Value | Pressure | Leadership | Volume | Trend |
|---|---|---|---|---|---|---|---|---|
| 7 Aug 2026 | 4.32 EUR | 0.8% | 4.22 EUR | 4.12 EUR | 1.03 | -3.89 | 180.0K | Off |
| 31 Jul 2026 | 4.28 EUR | -0.3% | 4.21 EUR | 4.12 EUR | 0.89 | -2.12 | 159.4K | Off |
| 24 Jul 2026 | 4.29 EUR | -2.6% | 4.21 EUR | 4.11 EUR | 0.68 | 0.10 | 53.8K | Off |
| 17 Jul 2026 | 4.41 EUR | 3.6% | 4.21 EUR | 4.11 EUR | 0.39 | 3.93 | 120.2K | Off |
| 10 Jul 2026 | 4.26 EUR | 0.6% | 4.20 EUR | 4.11 EUR | -0.25 | -0.48 | 42.1K | Off |
| 3 Jul 2026 | 4.23 EUR | 4.1% | 4.19 EUR | 4.10 EUR | -0.70 | -3.85 | 6.9K | Off |
| 26 Jun 2026 | 4.07 EUR | 5.9% | 4.19 EUR | 4.10 EUR | -1.09 | -3.66 | 2.8K | Off |
| 19 Jun 2026 | 3.84 EUR | -2.4% | 4.19 EUR | 4.09 EUR | -1.32 | -10.36 | 18.5K | Off |
| 12 Jun 2026 | 3.93 EUR | 0.4% | 4.21 EUR | 4.09 EUR | -1.30 | -7.27 | 3.0K | Off |
| 5 Jun 2026 | 3.92 EUR | 0.3% | 4.21 EUR | 4.09 EUR | -1.27 | -8.44 | 6.7K | Off |
| 29 May 2026 | 3.91 EUR | -2.5% | 4.22 EUR | 4.09 EUR | -1.16 | -10.37 | 34.1K | Off |
| 22 May 2026 | 4.00 EUR | 4.4% | 4.22 EUR | 4.09 EUR | -1.14 | -7.79 | 59.3K | Off |
| 15 May 2026 | 3.83 EUR | -1.1% | 4.22 EUR | 4.08 EUR | -1.11 | -8.68 | 104.5K | Off |
| 8 May 2026 | 3.88 EUR | -2.3% | 4.22 EUR | 4.08 EUR | -1.07 | -9.52 | 156.9K | Off |
How to use this report
This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.